RxDoctor Payments Data

Ankur Bindal

Psychiatry · Chula Vista, CANPI 1588820880

Payments from drug & device makers

$26,686in general payments, 2019–2025

Across 283 payments — averaging $94.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$17K
  • Neuronetics, Inc.$6K
  • Alkermes, Inc.$640
  • Janssen Scientific Affairs, LLC$400
  • Neurocrine Biosciences, Inc.$349
  • Sunovion Pharmaceuticals Inc.$346
  • plus $2K from 16 others

What the payments were for

  • Consulting fees$2,80010%
  • Speaking & faculty fees$15,74559%
  • Travel & lodging$5612%
  • Food & beverage$7,48128%
  • Education$980%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,686 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$235,868
Medicare patients
94
Services billed
1,617

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Aripiprazole58$5,263
Lurasidone Hcl11$5,083
Desvenlafaxine Succinate ErDesvenlafaxine Succinate38$3,641
Bupropion XlBupropion Hcl103$2,336
Quetiapine Fumarate72$1,396
Buspirone Hcl101$1,231
Duloxetine Hcl67$1,181
Venlafaxine Hcl ErVenlafaxine Hcl67$947
Trazodone Hcl88$581
Fluoxetine Hcl52$437
Sertraline Hcl37$428
Hydroxyzine Pamoate44$331
Escitalopram Oxalate58$306
Lamotrigine28$185
Gabapentin18$150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$17$42837 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →